Loading
A phase 3 trial of Pembrolizumab, Belzutifan and Lenvatinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study is a phase 3 interventional study registered as NCT05899049 by Merck Sharp & Dohme LLC, with 251 participants enrolled, started 2022-07-27 and due to reach its primary completion in 2026-02-04. Interventions recorded: Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab and Lenvatinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belzutifan, Lenvatinib, Anti-angiogenic therapy, Merck & Co. (MSD) and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma, Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Lenvatinib, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Eisai, Belzutifan, Lenvatinib, Anti-angiogenic therapy and the tag pipeline.
Shares Lenvatinib, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/